

Attorney Docket # 4904-4

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of

Miroslav Colic et al.

Serial No.: 09/640,218

Filed: August 16, 2000

For: Therapeutic and Prophylactic Compositions  
Including Catalytic Biomimetic Solids and  
Methods to Prepare and Use Them

Examiner: J. T. Woitach  
Group Art: 1632

I hereby certify that this correspondence is being  
deposited with the United States Postal Service with  
sufficient postage as first class mail in an envelope  
addressed to: Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450, on

July 28, 2003

(Date of Deposit)

Kent H. Cheng

Name of applicant, assignee or Registered Representative

Signature

July 28, 2003

Date of Signature

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

S I R:

In compliance with the duty of disclosure under 37 C.F.R. §1.56 and in accordance with the practice under 37 C.F.R. §§1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO 1449. Copies of the listed documents are also enclosed.

This information is being submitted subsequent to the later of three months after the filing date of the present application or the mailing of the first Office Action on the merits, but before the mailing of the Notice of Allowance.

STATEMENT

No item of information contained in the Information Disclosure Statement was cited in a communication received from a foreign Patent Office in a counterpart foreign


application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

In accordance with 37 C.F.R §§1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.

A check in the amount of \$180.00 in payment of the appropriate fee is enclosed.

It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO/SB/08a be returned indicating that such information has been considered.

Respectfully submitted,  
COHEN, PONTANI, LIEBERMAN & PAVANE

By:   
Kent H. Cheng  
Reg. No. 33,849  
551 Fifth Avenue, Suite 1210  
New York, New York 10176  
(212) 687-2770

Dated: July 28, 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/640,218
		Filing Date	August 16, 2000
		First Named Inventor	Miroslav Colic
		Art Unit	1632
		Examiner Name	J. T. Woitach
Sheet 1 of 2	Attorney Docket Number	4904-4	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind-Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> - Kind-Code <sup>5</sup> (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form call 1-800-PTO-0190 (1-800-786-0190) and select option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

**Complete if Known**

Application Number	09/640,218
Filing Date	August 16, 2000
First Named Inventor	Miroslav Colic
Art Unit	1632
Examiner Name	J. T. Woitach
Attorney Docket Number	4904-4

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Bai et al., "Promoter activation and following induction of the p21/WAF1 gene by flavone is involved in G <sub>1</sub> phase arrest in A549 lung adenocarcinoma cells", <i>FEBS Letters</i> 437, 61-64 (1998).	
		De Azevedo et al., "Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase", <i>Proc. Natl. Acad. Sci.</i> , vol. 93, pp. 2735-2740 (April 1995).	
		Mumpton, Frederick, "La roca magica: Uses of natural zeolites in agriculture and industry", <i>Proc. Natl. Acad. Sci.</i> , vol. 96, pp. 3463-3470, (March 1999).	
		Ahmad et al., "Green Tea Constituent Epigallocatechin-3-Gallate and Induction of Apoptosis and Cell Cycle Arrest in Human Carcinoma Cells", <i>Journal of the National Cancer Institute</i> , vol. 89, No. 24 (December 17, 1997).	
		Carlson et al., "Flavopiridol Induces G <sub>1</sub> Arrest with Inhibition of Cyclin-dependent Kinase (CDK) 2 and CDK4 in Human Breast Carcinoma Cells", <i>Cancer Research</i> 56, 2973-2978, (July 1, 1996).	
		Liu et al., "The herbal medicine sho-saiko-to inhibits the growth of malignant melanoma cells by upregulating Fas-mediated apoptosis and arresting cell cycle through downregulation of cyclin dependent kinases", <i>International Journal of Oncology</i> 12, 1321-1326 (1998).	
		Lu et al., "Epigallocatechin suppression of proliferation of vascular smooth muscle cells: correlation with c-jun and JNK", <i>British Journal of Pharmacology</i> , 124, pp. 1227-1237 (1998).	
		Miyagawa et al., "Protective Effect of Green Tea Extract and Tea Polyphenols against the Cytotoxicity of 1,4-Naphthoquinone in Isolated Rat Hepatocytes", <i>Biosci. Biotech. Biochem.</i> , vol. 61, pp. 1901-1905 (1997).	
		Rochelle et al., "Interactions between Hydroxocobalamin and Nitric Oxide (NO): Evidence for a Redox Reaction between NO and Reduced Cobalamin and Reversible NO Binding to Oxidized Cobalamin", <i>Journal of pharmacology and Experimental Therapeutics</i> vol. 275, No. 1, pp. 48-52 (1995).	
		Sadzuka et al., "Modulation of Cancer Chemotherapy by Green Tea", <i>Clinical Cancer Research</i> , vol. 4, pp. 153-156 (1998).	
		Shimizu et al., "Experimental Study of Antitumor Effect of Methyl-B <sub>12</sub> ", <i>Oncology</i> 44, 169-173 (1987).	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form call 1-800-PTO-0199 (1-800-786-9199) and select option 2